239 related articles for article (PubMed ID: 34668225)
1. Harnessing autophagy to fight SARS-CoV-2: An update in view of recent drug development efforts.
Rein T
J Cell Biochem; 2022 Feb; 123(2):155-160. PubMed ID: 34668225
[TBL] [Abstract][Full Text] [Related]
2. Autophagy as an emerging target for COVID-19: lessons from an old friend, chloroquine.
Bonam SR; Muller S; Bayry J; Klionsky DJ
Autophagy; 2020 Dec; 16(12):2260-2266. PubMed ID: 32522067
[TBL] [Abstract][Full Text] [Related]
3. Open questions for harnessing autophagy-modulating drugs in the SARS-CoV-2 war: hope or hype?
Brest P; Benzaquen J; Klionsky DJ; Hofman P; Mograbi B
Autophagy; 2020 Dec; 16(12):2267-2270. PubMed ID: 32521191
[TBL] [Abstract][Full Text] [Related]
4. Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV.
Aherfi S; Pradines B; Devaux C; Honore S; Colson P; Scola B; Raoult D
Future Microbiol; 2021 Nov; 16():1341-1370. PubMed ID: 34755538
[TBL] [Abstract][Full Text] [Related]
5. Can endolysosomal deacidification and inhibition of autophagy prevent severe COVID-19?
Morris G; Athan E; Walder K; Bortolasci CC; O'Neil A; Marx W; Berk M; Carvalho AF; Maes M; Puri BK
Life Sci; 2020 Dec; 262():118541. PubMed ID: 33035581
[TBL] [Abstract][Full Text] [Related]
6. From hydroxychloroquine to ivermectin: what are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2?
Rakedzon S; Neuberger A; Domb AJ; Petersiel N; Schwartz E
J Travel Med; 2021 Feb; 28(2):. PubMed ID: 33480414
[TBL] [Abstract][Full Text] [Related]
7. Elucidating the Drug Repurposing Spectra of COVID-19 with its Analogues SARS and MERS.
Mishra J; Prasun C; Sahoo PK; Nair MS
Mini Rev Med Chem; 2021; 21(20):3191-3202. PubMed ID: 33632095
[TBL] [Abstract][Full Text] [Related]
8. Facts and Myths: Efficacies of Repurposing Chloroquine and Hydroxychloroquine for the Treatment of COVID-19.
Al-Bari AA
Curr Drug Targets; 2020; 21(16):1703-1721. PubMed ID: 32552642
[TBL] [Abstract][Full Text] [Related]
9. The lysosome: A potential juncture between SARS-CoV-2 infectivity and Niemann-Pick disease type C, with therapeutic implications.
Ballout RA; Sviridov D; Bukrinsky MI; Remaley AT
FASEB J; 2020 Jun; 34(6):7253-7264. PubMed ID: 32367579
[TBL] [Abstract][Full Text] [Related]
10. Small-molecule Antiviral Agents in Ongoing Clinical Trials for COVID-19.
Apaydın ÇB; Çınar G; Cihan-Üstündağ G
Curr Drug Targets; 2021; 22(17):1986-2005. PubMed ID: 33588727
[TBL] [Abstract][Full Text] [Related]
11. Drugs, Metabolites, and Lung Accumulating Small Lysosomotropic Molecules: Multiple Targeting Impedes SARS-CoV-2 Infection and Progress to COVID-19.
Blaess M; Kaiser L; Sommerfeld O; Csuk R; Deigner HP
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670304
[TBL] [Abstract][Full Text] [Related]
12. Docking study of chloroquine and hydroxychloroquine interaction with RNA binding domain of nucleocapsid phospho-protein - an
Amin M; Abbas G
J Biomol Struct Dyn; 2021 Aug; 39(12):4243-4255. PubMed ID: 32469265
[TBL] [Abstract][Full Text] [Related]
13. Inhibitors of endosomal acidification suppress SARS-CoV-2 replication and relieve viral pneumonia in hACE2 transgenic mice.
Shang C; Zhuang X; Zhang H; Li Y; Zhu Y; Lu J; Ge C; Cong J; Li T; Tian M; Jin N; Li X
Virol J; 2021 Feb; 18(1):46. PubMed ID: 33639976
[TBL] [Abstract][Full Text] [Related]
14. Niclosamide-A promising treatment for COVID-19.
Singh S; Weiss A; Goodman J; Fisk M; Kulkarni S; Lu I; Gray J; Smith R; Sommer M; Cheriyan J
Br J Pharmacol; 2022 Jul; 179(13):3250-3267. PubMed ID: 35348204
[TBL] [Abstract][Full Text] [Related]
15. Chloroquine and its derivatives in the management of COVID-19: A scoping review.
Pimentel J; Andersson N
Biomedica; 2020 Oct; 40(Supl. 2):80-95. PubMed ID: 33152192
[TBL] [Abstract][Full Text] [Related]
16. Repositioning Ivermectin for Covid-19 treatment: Molecular mechanisms of action against SARS-CoV-2 replication.
Low ZY; Yip AJW; Lal SK
Biochim Biophys Acta Mol Basis Dis; 2022 Feb; 1868(2):166294. PubMed ID: 34687900
[TBL] [Abstract][Full Text] [Related]
17. On-target versus off-target effects of drugs inhibiting the replication of SARS-CoV-2.
Sauvat A; Ciccosanti F; Colavita F; Di Rienzo M; Castilletti C; Capobianchi MR; Kepp O; Zitvogel L; Fimia GM; Piacentini M; Kroemer G
Cell Death Dis; 2020 Aug; 11(8):656. PubMed ID: 32814759
[TBL] [Abstract][Full Text] [Related]
18. Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.
Alonzi T; Aiello A; Petrone L; Najafi Fard S; D'Eletto M; Falasca L; Nardacci R; Rossin F; Delogu G; Castilletti C; Capobianchi MR; Ippolito G; Piacentini M; Goletti D
Cells; 2021 Dec; 11(1):. PubMed ID: 35011614
[TBL] [Abstract][Full Text] [Related]
19. Existing highly accumulating lysosomotropic drugs with potential for repurposing to target COVID-19.
Norinder U; Tuck A; Norgren K; Munic Kos V
Biomed Pharmacother; 2020 Oct; 130():110582. PubMed ID: 32763818
[TBL] [Abstract][Full Text] [Related]
20. Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion.
Coleman CM; Sisk JM; Mingo RM; Nelson EA; White JM; Frieman MB
J Virol; 2016 Oct; 90(19):8924-33. PubMed ID: 27466418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
